Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D.
Cortes JE, et al.
Leukemia. 2024 Jul;38(7):1522-1533. doi: 10.1038/s41375-024-02278-8. Epub 2024 May 16.
Leukemia. 2024.
PMID: 38755421
Free PMC article.
Clinical Trial.
Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1(T315I), which is resistant to most approved adenosine triphosphate-competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability …
Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1(T315I), which is resistant to most approved aden …